Nascent Biotech Competitors and Similar CompaniesClear all
Nascent Biotech's competitors and similar companies include VECT-HORUS, Gamida Cell, Innate Pharma and OncoDNA.
 VECT-HORUS VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors. |  Gamida Cell Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. |  Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. |  OncoDNA OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients. | ||
Founding Date | Founding Date 2014 | Founding Date 2005 | Founding Date 1998 | Founding Date 1999 | Founding Date 2012 |
Type | Type Public | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Marseille, FR HQ | Locations Boston, US HQ Jerusalem, IL | Locations Marseille, FR HQ Rockville, US | Locations Charleroi, BE HQ |
Employees | Employees N/A | Employees 512% increase | Employees 143175% increase | Employees 181 | Employees 502% increase |
Valuation ($) | Valuation ($) 13.8 m | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) 148.6 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $1.8m (FY, 2023) | Revenue (est.) €2.8m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $319.5k (FY, 2024) | Cost of goods N/A | Cost of goods $1.5m (FY, 2023) | Cost of goods €266k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $330k (FY, 2023) | Gross profit €8.7m (FY, 2025) | Gross profit N/A |
Net income | Net income ($2.1m) (FY, 2024) | Net income N/A | Net income ($63m) (FY, 2023) | Net income (€49.2m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 14.5m (over 5 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 20.6m (over 6 years ago) |
Total funding raised | Total funding raised $ 2m | Total funding raised $ 29.4m | Total funding raised $ 128.3m | Total funding raised $ 94.1m | Total funding raised $ 29.8m |
For sources of this data, please see the company profile
View Company Profiles
VECT-HORUS
HQ
Marseille, FR
Employees
51↑ 2% increase
VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors.
View companyGamida Cell
HQ
Boston, US
Employees
143
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases.
View companyInnate Pharma
HQ
Marseille, FR
Employees
181
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
View companyOncoDNA
HQ
Charleroi, BE
Employees
50↑ 2% increase
OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients.
View company